ArticleScientific reports2026
Comparative study of palmitoleic acid, sea buckthorn oil, and lovastatin in hepatocellular steatosis model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sea Buckthorn (Foods (Basel, Switzerland) · 2026Review
- The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026Review
- Wanshi Shachong Xiaoji Pills Alleviate Functional Dyspepsia in Mice and Exhibit Lipid-Lowering Effects in a Hepatocyte Steatosis Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Palmitoleic acid (POA) has been associated with various metabolic effects, including regulating lipid metabolism and cholesterol production. In this study, we explored the impact of both cis- (cPOA) and trans-palmitoleic acid (tPOA), along with sea buckthorn oil (SBO), a natural source rich in cPOA, on lipid content, metabolic activity, and Rap1 prenylation in HepG2 cells. We employed a free fatty acids-induced steatosis model. Our findings revealed that neither cPOA, tPOA, SBO, nor digested SBO impaired the metabolic activity of HepG2 cells, even under steatotic conditions. All treatments led to triacylglycerol (TAG) accumulation, with tPOA demonstrating the beneficial effect. While cholesterol levels remained unchanged in normal cells, a reduction was noted in steatotic cells, comparable to the effect of lovastatin. Molecular docking suggested that both POA isomers may bind and block the catalytic pocket of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). To further explore this, we examined their influence on Rap1 prenylation and subcellular localization. Under steatotic conditions, both POA isomers, particularly at concentrations of 50 and 100 µM, elevated cytosolic Rap1 levels, whereas no significant changes were observed in membrane or cytosolic Rap1a protein levels in normal HepG2 cultures. Notably, unlike lovastatin, POA isomers and digested SBO enhanced glucose-stimulated insulin secretion from pancreatic cells. Our results highlight the potential of POA isomers and SBO as modulators of lipid metabolism, cholesterol production, and insulin secretion, suggesting their relevance in managing metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.